ArticleFuture microbiology2025
Synergistic drug strategy against mastitis-associated MRSA strains.
Article in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the resistance profiles of mastitis-associated methicillin-resistant Staphylococcus aureus (MRSA) and to evaluate the synergistic antibacterial effects of antibiotic combinations.
methodsTwenty clinical isolates obtained from patients with lactational mastitis underwent antimicrobial susceptibility testing. Six multidrug-resistant (MDR) isolates were selected to assess pairwise combinations of 10 antibiotics by checkerboard assays and to confirm bactericidal synergy via time-kill testing. In vivo efficacy of the combinations was assessed in a Galleria mellonella infection model.
resultsOver 90% of the isolates were MRSA, with high resistance to oxacillin, clindamycin, and gentamicin; several also displayed elevated minimum inhibitory concentrations (MICs) of vancomycin. Vancomycin plus oxacillin (VAN+OXA) or rifampicin (VAN+RIF) showed consistent in vitro synergy. VAN+OXA produced the greatest killing, reducing bacterial counts by > 3 log₁₀ CFU/mL at 24 h. In vivo, both combinations significantly improved larval survival versus monotherapy across multiple strains.
conclusionsVAN combined with OXA or RIF exhibited robust synergy against mastitis-linked MDR-MRSA in vitro and in vivo. These findings highlight that the combination of VAN with OXA or RIF could be a promising strategy for treating mastitis caused by drug-resistant MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.